Amicus Therapeutics, Inc. (FOLD)
NASDAQ: FOLD · Real-Time Price · USD
7.24
+0.05 (0.70%)
Aug 14, 2025, 11:39 AM - Market open
Amicus Therapeutics Analyst Ratings
Total Analysts
10
Consensus Rating
Strong Buy
Price Target
$26.89
Upside
+271.41%
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Hold → Buy Upgrades $102 → $108 | Hold → Buy | Upgrades | $102 → $108 | +1,391.71% | Jul 17, 2025 |
| UBS | UBS | Strong Buy Maintains $21 → $22 | Strong Buy | Maintains | $21 → $22 | +203.87% | May 2, 2025 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $12 → $9 | Hold | Maintains | $12 → $9 | +24.31% | May 2, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $18 → $17 | Buy | Maintains | $18 → $17 | +134.81% | Feb 20, 2025 |
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Feb 20, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $21 | Buy | Reiterates | $21 | +190.06% | Jan 15, 2025 |
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Jan 13, 2025 |
| Morgan Stanley | Morgan Stanley | Buy → Hold Downgrades $17 → $12 | Buy → Hold | Downgrades | $17 → $12 | +65.75% | Dec 13, 2024 |
| JP Morgan | JP Morgan | Buy Maintains $16 → $17 | Buy | Maintains | $16 → $17 | +134.81% | Nov 12, 2024 |
| UBS | UBS | Strong Buy Maintains $19 → $21 | Strong Buy | Maintains | $19 → $21 | +190.06% | Nov 7, 2024 |
| Guggenheim | Guggenheim | Strong Buy Maintains $13 → $15 | Strong Buy | Maintains | $13 → $15 | +107.18% | Nov 7, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $20 → $21 | Buy | Maintains | $20 → $21 | +190.06% | Nov 7, 2024 |
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Nov 7, 2024 |
| B of A Securities | B of A Securities | Strong Buy Maintains $13 → $15 | Strong Buy | Maintains | $13 → $15 | +107.18% | Oct 17, 2024 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $19 → $18 | Buy | Maintains | $19 → $18 | +148.62% | Oct 11, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $20 | Buy | Reiterates | $20 | +176.24% | Sep 20, 2024 |
Upgrade to Pro
Get stock forecasts from Wall Street's highest rated professionals
Get much more with Stock Analysis Pro
- Investment ideas from the top Wall Street analysts
- Unlimited access to all data and tools
- Advanced analyst filtering and sorting options
- Up to 10 years of analyst rating history
Analyst Star Rankings
Our analyst star rankings are based on these four factors
- Success Rate
- The percentage of ratings that are profitable.
- Average Return
- The average percentage return within one year of the rating.
- Rating Count
- The more ratings the analyst has provided, the higher the score.
- Recency
- Ratings provided within the past year contribute to a higher score.